A Phase II Study Of Twenty-Four Hour Infusion Gemcitabine For Advanced Colorectal Cancer
- Determine the response rate in patients with advanced colorectal cancer treated with
- Determine the toxic effects of this drug in these patients.
- Determine the progression-free survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive gemcitabine IV continuously over 24 hours on days 1, 8, and 15. Treatment
repeats every 28 days for a total of 6 courses in the absence of disease progression or
Patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 12-41 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Paul D. Savage, MD
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center||Winston-Salem, North Carolina 27157-1082|